TriLink Announces Sales and License Agreement with Glen Research for CleanAmp™ Amidites
News Jun 25, 2009
TriLink BioTechnologies (TriLink), announced that it has signed a sales and license agreement with Glen Research Corporation to sell TriLink's CleanAmp™ Amidites.
Glen Research can now sell the patented CleanAmp™ Amidites produced by TriLink to third parties for use in the production of CleanAmp™ Primers.
TriLink's CleanAmp™ technology offers a less expensive approach to high stringency PCR. CleanAmp™ is a unique solution, where the primer or dNTP components of the PCR reaction mix, rather than the enzymes are modified.
Making the CleanAmp™ Amidites available through Glen Research allows institutions with oligonucleotide synthesis capabilities to manufacture CleanAmp™ Primers in-house.
"Glen Research is dedicated to bringing the very best research products to the oligonucleotide synthesis market. So we are delighted to be able to offer CleanAmp™ Amidites in partnership with TriLink. We feel that the CleanAmp™ Amidites will make an excellent addition to our repertoire of products for DNA research," said Glen Research President/CEO, Dr. Hugh Mackie.
"TriLink and Glen Research have a long standing relationship built on a shared interest in advancing science through the highest quality reagents and technical expertise. We feel Glen Research is the perfect partner for bringing CleanAmp™ Amidites to the marketplace," said TriLink CEO, Dr. Richard Hogrefe.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019